Breaking News

Lilly First-Quarter Adjusted Earnings 70c per Share, In Line With Estimates
Tweet TWEET

Roche’s Perjeta for Breast Cancer Wins Approval

(Corrects drug spelling in headline, second paragraph of story published June 8.)

Roche Holding AG (ROG)’s personalized drug treatment for a fast-growing type of breast cancer won approval from U.S. regulators.

Perjeta, chemically known as pertuzumab, is designed to work with the Basel, Switzerland-based company’s Herceptin and chemotherapy to attack breast cancer that has spread in patients who have a certain gene mutation. The Food and Drug Administration today cleared Perjeta for consumer use, Roche’s Genentech unit said in a statement.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.